See ratings and reviews when you sign up for an account.

A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria

This study is currently Recruiting

March 2010 By Faes Farma, S.A.

First Recieved on March 4, 2010

Last Updated on March 4, 2010

Sponsor: Faes Farma, S.A.
Information provided by: Faes Farma, S.A.
Identifier: NCT01081574


The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population subset.

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:2 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: 1. Either sex aged from ? 2 to < 12 years of age. Female subjects must not be of child bearing potential. 2. Height and weight within a majority range (e.g., 25th through 75th percentile) of the subject's age and sex as provided in national tables. 3. Documented history of SAR/PAR or CU at the time of inclusion. Subjects must be symptomatic at screening as judged by the investigator. 4. A documented positive skin prick test or IgE test (RAST) for at least one seasonal or perennial allergen in children with AR obtained within the 12 months prior to inclusion. 5. Excepting AR or CU, judged to be in general good health based on medical history, physical examination and clinical laboratory tests, with a QTc duration on the ECG recorded at screening within the normal range (? 440 msec). 6. Written informed consent signed by the legal representative of the minor (his/her parent(s) or a person legally appointed if different from parent(s)) and, where applicable, assent signed by the child, according to local regulations. Exclusion Criteria: 1. Female subjects of childbearing potential. If menarche occurs after study enrolment and during the dosing period, the subject should be discontinued from the treatment and followed up for safety as per protocol. Occurrence of menarche in the course of the study should always be documented. 2. Intake of another investigational medication in another clinical study within 30 days prior to the first study drug intake. 3. Clinically significant ECG abnormalities as judged by the investigator (e.g., Wolff-Parkinson-White [WPW] syndrome, long QT syndrome). 4. Known allergy/hypersensitivity to the study drug or its inactive ingredients. 5. Any clinical conditions or circumstances that in the opinion of the investigator would make the subject unsuitable for the study (e.g., hepatic impairment, renal impairment, mental impairment, cardiac disease). 6. Subjects with known positive Hepatitis B surface antigen (Hbs Ag), or Hepatitis C antibody or who are known to be human immunodeficiency virus (HIV) positive. No testing will be required for this study. 7. Subjects who are expected to take during the study period or have taken any of the following medications prior to inclusion in the study and have not complied with the specified wash out period of 7 days unless otherwise noted: - Oral corticosteroids. - Oral antihistamines: loratadine, desloratadine, and fexofenadine. - Anti-leukotrienes - Amoxicillin, benzylpenicillin, and macrolide antibiotics and imidazolic antifungals (systemic) - Omeprazol - Aspirin, ibuprofen - Carbamazepine - St. John's Wort (15 days) 8. Hypersensitivity to H1 antihistamines or benzimidazoles. 9. Ingestion of citrus fruits and cranberries or any fruit juice or any other well known PgP or organic anion transporter polypeptide (OATP) inhibitor, inducer, or substrate (see Appendix C) within 7 days prior to first dose of study medication. 10. Mentally disabled minors or Minors who by official order have been institutionalised (e.g., in orphanages) must be excluded from participation. 11. Minors who explicitly refuse to take part in the study.


  • Investigator: Ulrich Wahn, Prof. - Principal Investigator - International Coordinating Investigator. Charit? - Universit?tsmedizin Berlin (Germany)
  • Investigator: Regina F?ster-Holst, Prof. Dr. med. - Principal Investigator - Universit?ts-Hautklinik Kiel (Germany)
  • Investigator: Bel?n S?daba, Dr. med. - Principal Investigator - Cl?nica Universitaria de Navarra (Spain)
  • Investigator: Gunilla Hedlin, Prof. Dr. med - Principal Investigator - Karolinska University Hospital


  • Charit? - Universit?tsmedizin. Campus Virchow-Klinikum. Klinik f?r P?diatrie mit Schwerpunkt Pneumologie/Immunologie

    Berlin, 13353 Germany

  • Universit?ts-Hautklinik

    Kiel, 24105 Germany

  • Cl?nica Universitaria de Navarra

    Pamplona, Navarra 31008 Spain

  • Karolinska University Hospital. Astrid Lindgren's Hospital

    Stockholm, 17176 Sweden

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.